摘要
目的探讨程序性死亡配体-1(PD-L1)在非小细胞肺癌(NSCLC)组织中表达及对患者预后的影响。方法选取江苏省中医院病理科收集的90例NSCLC组织(NSCLC组)、40例癌旁正常肺组织作为癌旁正常组进行免疫组化检测,对比两组标本中的PD-L1蛋白阳性表达率。根据PD-L1蛋白表达是否为阳性,将90例NSCLC分为PD-L1阳性组和PD-L1阴性组。结果NSCLC组的PD-L1蛋白阳性表达(80.00%)高于癌旁正常组(5.00%,P<0.05)。90例NSCLC中PD-L1阳性组72例和PD-L1阴性组18例。PD-L1蛋白阳性表达的NSCLC患者3年生存率(19.70%)显著低于阴性患者(52.94%,P<0.05);PD-L1蛋白阳性表达的NSCLC患者的生存时间21.0月显著低于PD-L1蛋白阴性表达患者的28.0月(P<0.05)。肿瘤淋巴结转移(TNM)分期增高、发生淋巴结转移、PD-L1蛋白阳性表达是NSCLC患者不良预后的独立危险因素(P<0.05)。结论PD-L1在NSCLC组织中表达程度上调,并且与患者肿瘤发生、发展及不良预后具有显著的关系。
Aim To explore the expression of programmed death ligand-1(PD-L1)in non-small cell lung cancer(NSCLC)and its influence on the prognosis of patients.Methods The 90 cases of NSCLC tissues(NSCLC group)and 40 cases of non-small cell lung cancer paracancerous tissues collected by the department of pathology,Jiangsu provincial hospital of traditional chinese medicine were selected as the adjacent group for immunohistochemical detection,and the positive expression rates of PD-L1 protein in the two groups of specimens were compared.The NSCLC of 90 cases were divided into PD-L1 positive group and PD-L1 negative group according to whether the expression of PD-L1 protein positive.Results The positive expression of PD-L1 protein in the case group was higher(80.00%)than in the adjacent group(5.00%,P<0.05).There are 72 cases PD-L1 positive group and 18 cases PD-L1 negative group in NSCLC of 90 cases.The 3-year survival rate of NSCLC patients with positive expression of PD-L1 protein was significantly lower than(19.70%)in negative patients(52.94%,P<0.05);The survival time of NSCLC patients with positive PD-L1 protein expression(21.0 months)was significantly lower than that of patients with negative PD-L1 protein expression(28.0 months,P<0.05).Increased tumor node metastasis(TNM)staging,lymph node metastasis,and positive expression of PD-L1 protein are independent risk factors for poor prognosis in NSCLC patients(P<0.05).Conclusion PD-L1 is up-regulated in NSCLC tissues,and it has a significant relationship with tumor occurrence,development and poor prognosis.
作者
曾雪华
吴刚
祁永健
ZENG Xuehua;WU Gang;QI Yongjian(Department of Respiratory Medicine,South Hospital of Jiangsu Provincial Hospital of Traditional Chinese Medicine,Nanjing,Jiangsu 210029,China)
出处
《中南医学科学杂志》
CAS
2021年第1期31-34,57,共5页
Medical Science Journal of Central South China
基金
江苏省卫生厅面上项目(H201064)。
关键词
程序性死亡配体-1
非小细胞肺癌
预后
programmed death ligand-1
non-small cell lung cancer
prognosis